Imaging3 (OTC:IMGG) jumped more than 30 percent today on heavy volume after announcing the hiring of a prestigious law firm for FDA consulting. In early trading, shares of Imaging3 were up 34 percent at $0.21 per share on volume of 2.5 million shares compared to its average daily volume of about 1.6 million shares. Imaging3 has a market cap of $79 million and a 52-week range between $0.08 and $1.95 per share.
Imaging3, developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, today announced the hiring of the law firm McDermott Will & Emery as an FDA consultant.
Dean Janes, Chairman and CEO of Imaging3, commented, "We are pleased to announce the hiring of McDermott Will & Emery as an FDA consultant and legal counsel; management is looking forward to working with this prestigious firm to develop our FDA filing strategy for our DViS product. McDermott Will & Emery have the legal, medical and scientific background along with the experience of former FDA personnel to assist Imaging3 in building a solid strategy for a successful FDA application," further stated Mr. Janes.
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,000 lawyers, the firm has offices in Boston, Brussels, Chicago, Dusseldorf, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Rome, San Diego, Silicon Valley and Washington, D.C.
Imaging3, founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body.
Visit the company's website at http://www.imaging3.com for more information
No comments:
Post a Comment